Physicians should understand and be sensitive to all of the issues that affect patients when they prescribe the tertogenic medication isotretinoin for treatment of acne vulgaris.
Stanford University Medical School established a positive partnership with a pharmaceutical company to offer an industry-sponsored resident elective course in a way that minimizes conflict of interest and has been accepted by the ACGME.
Two physicians give an overview of the iPledge program and discuss the problematic aspects of the program for physicians who prescribe isotretinoin and their patients.
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
A physician argues that pharmaceutical industry support for residency programs creates a conflict of interest and compromises the educational integrity of the programs.